Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Verboven

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Applied Optics|October 12, 2004
Fourier fringe processing by use of an interpolated Fourier-transform techniqueSteve Vanlanduit, Joris Vanherzeele, Patrick Guillaume, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2013
Pharmacokinetic interaction between telaprevir and methadoneRolf van Heeswijk, Peter Verboven, Ann Vandevoorde, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 17, 2021
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinibLoeckie De Zwart, Jan Snoeys, Frank Jacobs, et al.
Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.
Chemical Research in Toxicology|December 11, 2024
CYP3A4-Mediated Bioactivation of the β-Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor JNJ-54861911 Results in Redox-Neutral Addition of Glutathione via Catalysis by Glutathione S-Transferase α1, Identified as the Major Target Protein in Human HepatocytesLaurent Leclercq, Ronald de Vries, Valérie Koppen, et al.
British Journal of Clinical Pharmacology|November 19, 2016
In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozinRao N V S Mamidi, Shannon Dallas, Carlo Sensenhauser, et al.
Journal of Clinical Pharmacology|February 14, 2023
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic ImpairmentThomas N Kakuda, Atef Halabi, Gernot Klein, et al.
Gastroenterology|November 24, 2024
A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection ModelXin Zhang, Mara Klöhn, Sivi Ouwerkerk-Mahadevan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 27, 2023
Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small moleculesStephanie Kourula, Merel Derksen, Ferran Jardi, et al.
Chemmedchem|October 29, 2019
Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding BurdenKosuke Anan, Yasuyoshi Iso, Takuya Oguma, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Applied Optics|October 12, 2004
Fourier fringe processing by use of an interpolated Fourier-transform techniqueSteve Vanlanduit, Joris Vanherzeele, Patrick Guillaume, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2013
Pharmacokinetic interaction between telaprevir and methadoneRolf van Heeswijk, Peter Verboven, Ann Vandevoorde, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 17, 2021
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinibLoeckie De Zwart, Jan Snoeys, Frank Jacobs, et al.
Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.
Chemical Research in Toxicology|December 11, 2024
CYP3A4-Mediated Bioactivation of the β-Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor JNJ-54861911 Results in Redox-Neutral Addition of Glutathione via Catalysis by Glutathione S-Transferase α1, Identified as the Major Target Protein in Human HepatocytesLaurent Leclercq, Ronald de Vries, Valérie Koppen, et al.
British Journal of Clinical Pharmacology|November 19, 2016
In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozinRao N V S Mamidi, Shannon Dallas, Carlo Sensenhauser, et al.
Journal of Clinical Pharmacology|February 14, 2023
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic ImpairmentThomas N Kakuda, Atef Halabi, Gernot Klein, et al.
Gastroenterology|November 24, 2024
A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection ModelXin Zhang, Mara Klöhn, Sivi Ouwerkerk-Mahadevan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 27, 2023
Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small moleculesStephanie Kourula, Merel Derksen, Ferran Jardi, et al.
Chemmedchem|October 29, 2019
Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding BurdenKosuke Anan, Yasuyoshi Iso, Takuya Oguma, et al.
Pageof 1